智飞生物：重组带状疱疹ZFA01佐剂疫苗（CHO细胞）临床试验申请获得受理

Core Viewpoint - Zhifei Biological's subsidiary, Zhifei Longkema, has received the clinical trial application acceptance notice from the National Medical Products Administration for its recombinant varicella-zoster virus vaccine ZFA01 adjuvanted with CHO cells [1] Group 1 - The vaccine ZFA01 is designed to target shingles, a disease caused by the varicella-zoster virus [1] - The acceptance of the clinical trial application marks a significant step in the development of this vaccine [1]